Evaluating the impact of PCI on patients with chronic coronary artery occlusion
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion
The First Affiliated Hospital with Nanjing Medical University · NCT06542653
This study is testing if a heart procedure called PCI can help people with chronic coronary artery blockages live longer and have fewer serious heart problems compared to those who only receive medication.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 258 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University (other) |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06542653 on ClinicalTrials.gov |
What this trial studies
This study assesses the long-term clinical outcomes of patients with chronic total occlusions (CTOs) who underwent percutaneous coronary intervention (PCI) compared to those receiving optimal medical therapy (OMT). Patients treated at the First Affiliated Hospital of Nanjing Medical University between January 2011 and December 2017 were divided into two groups based on their treatment. The primary focus is on major adverse cardiac cerebrovascular events (MACCE), including cardiac death and recurrent myocardial infarction, while secondary outcomes include all-cause mortality. The study aims to determine if PCI can provide better outcomes than OMT alone for CTO patients.
Who should consider this trial
Good fit: Ideal candidates are patients with at least one coronary CTO lesion who are being considered for PCI.
Not a fit: Patients with ST-segment elevation myocardial infarction (STEMI), a history of coronary artery bypass grafting (CABG), or other serious conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved long-term outcomes for patients with chronic total occlusions.
How similar studies have performed: Previous studies have indicated that PCI can improve outcomes in patients with CTOs, suggesting this approach has been successful in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with at least one coronary CTO lesion at our hospital in between January 2011 and December 2017 Exclusion Criteria: * (1) patients with ST-segment elevation myocardial infarction (STEMI) * (2)a history of coronary artery bypass grafting (CABG) * (3) cardiogenic shock * (4) malignant tumor. Patients were referred for PCI based on CTO-related symptoms or evidence of viability, or corresponding ischemia in the area of the CTO artery.
Where this trial is running
Nanjing, Jiangsu
- The First Affiliated Hospital with Nanjing Medical University — Nanjing, Jiangsu, China (RECRUITING)
Study contacts
- Study coordinator: Mei Wang
- Email: 1513267113@qq.com
- Phone: 0086 15256095215
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Atheroscleroses, Chronic total occlusion, Percutaneous coronary intervention, Major adverse cardiovascular events